Detailed information for compound 41329
Basic information
Technical information
- TDR Targets ID: 41329
- Name: (2-(Octahydro-1-azocinyl)ethyl)guanidine
- MW: 198.308 | Formula: C10H22N4
-
H donors: 2
H acceptors: 0
LogP: 0.84
Rotable bonds: 4
Rule of 5 violations (Lipinski): 1 - SMILES: NC(=N)NCCN1CCCCCCC1
- InChi: 1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)
- InChiKey: ACGDKVXYNVEAGU-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- .Beta.-1-Azacyclooctylethylguanidine
- 1-(2-azocan-1-ylethyl)guanidine
- 2-(1'-Azacyclooctyl)ethylguanidine
- 2-(1-N,N-Heptamethyleneimino)ethylguanidine
- 2-[2-(1-azocanyl)ethyl]guanidine
- 2-[2-(azocan-1-yl)ethyl]guanidine
- 55-65-2
- 60-02-6 (SULFATE SALT)
- Abapresin
- AIDS-155922
- AIDS155922
- Azocine, 1-((2-(aminoiminomethyl)amino)ethyl)octahydro-
- Azocine, 1-(2-guanidinoethyl)octahydro-
- BPBio1_000346
- BSPBio_000314
- BSPBio_002092
- C07036
- CAS-60-02-6
- DivK1c_000539
- Dopam
- Dopom
- EINECS 200-241-3
- Eutensol
- Guanethidine
- Guanethidine Monosulfate
- Guanethidine Sulphae
- Guanethidinum [INN-Latin]
- Guanetidina [INN-Spanish]
- Guanidine, [2-(hexahydro-1(2H)-azocinyl)ethyl]-
- Guanidine, N-[2-(hexahydro-1(2H)-azocinyl)ethyl]-
- Guanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)-
- Heptamethylenimine, 1-(2-guanidinoethyl)-
- HSDB 3092
- IDI1_000539
- KBio1_000539
- KBio2_001317
- KBio2_003885
- KBio2_006453
- KBio3_001312
- KBioGR_000976
- KBioSS_001317
- N-(2-Perhydroazocin-1-ylethyl)guanidine
- NCGC00016272-01
- NINDS_000539
- NSC29863 (SULFATE SALT)
- Octadin
- Octadine
- Octatensine
- Octatensin
- Oktadin
- Oktatensin
- Oktatenzin
- Prestwick0_000317
- Prestwick1_000317
- Prestwick2_000317
- Prestwick3_000317
- Sanotensin
- SPBio_001206
- SPBio_002533
- Spectrum2_001103
- Spectrum3_000446
- Spectrum4_000568
- Spectrum5_000784
- Spectrum_000837
- Su 5864 sulfate (1:1)
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.5569 | 0.5569 |
| Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0046 | 1 | 1 |
| Echinococcus granulosus | G protein coupled receptor 139 | 0.0046 | 1 | 1 |
| Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.5569 | 0.53 |
| Echinococcus multilocularis | 7TM GPCR, rhodopsin | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus multilocularis | lamin | 0.0033 | 0.5569 | 0.5569 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Schistosoma mansoni | adenoreceptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | growth hormone secretagogue receptor type 1 | 0.0046 | 1 | 1 |
| Echinococcus granulosus | allatostatin A receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | 5-hydroxytryptamine 2C receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus granulosus | g-protein coupled receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | G protein coupled 5 hydroxytryptamine receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | somatostatin receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Schistosoma mansoni | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | amine GPCR | 0.0046 | 1 | 1 |
| Brugia malayi | ORL1-like opioid receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Dopamine receptor protein 1, putative (partial) | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | melatonin receptor type 1A | 0.0046 | 1 | 1 |
| Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.5569 | 0.5569 |
| Brugia malayi | G protein-coupled receptor F59B2.13 | 0.0046 | 1 | 1 |
| Schistosoma mansoni | growth hormone secretagogue receptor | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | unidentified vitellogenin-linked transcript protein 6 | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | amine GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptide receptor | 0.0046 | 1 | 1 |
| Brugia malayi | RE15519p | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | 7tm_1 domain containing protein | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | G protein coupled 5 hydroxytryptamine receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Dopamine receptor protein 1 | 0.0046 | 1 | 1 |
| Echinococcus granulosus | orexin receptor type 2 | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | G-protein coupled receptor | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | g protein linked acetylcholine receptor gar 2a | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | g protein coupled receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptide Y receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | musashi | 0.0033 | 0.5569 | 0.5569 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptide receptor | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptides capa receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | allatostatin A receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide Y receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | thyrotropin releasing hormone receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | lamin dm0 | 0.0033 | 0.5569 | 0.5569 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Brugia malayi | GnHR receptor homolog | 0.0046 | 1 | 1 |
| Brugia malayi | Melatonin receptor type 1A | 0.0046 | 1 | 1 |
| Brugia malayi | intermediate filament protein | 0.0033 | 0.5569 | 0.53 |
| Echinococcus granulosus | biogenic amine 5HT receptor | 0.0046 | 1 | 1 |
| Brugia malayi | G-protein coupled receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | peptide (allatostatin/somatostatin)-like receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | opsin-like receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | ancient conserved domain protein 2 (cyclin m2) | 0.0046 | 1 | 1 |
| Brugia malayi | Dopamine receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | g protein linked acetylcholine receptor gar 2a | 0.0046 | 1 | 1 |
| Echinococcus granulosus | g protein coupled receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | tm gpcr rhodopsin | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | fmrfamide receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | g protein linked acetylcholine receptor gar 2a | 0.0046 | 1 | 1 |
| Schistosoma mansoni | hypothetical protein | 0.0046 | 1 | 1 |
| Brugia malayi | G-protein coupled receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | G-protein-linked acetylcholine receptor protein 2 | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine (octopamine/dopamine) receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | serotonin receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | G-protein coupled receptor, putative | 0.0046 | 1 | 1 |
| Echinococcus granulosus | g protein coupled receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine (dopamine) receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptides capa receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.5569 | 0.5569 |
| Schistosoma mansoni | histamine-responsive GPCR (AAF21638) | 0.0046 | 1 | 1 |
| Brugia malayi | putative neuropeptide receptor NPR1 | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | tachykinin peptides receptor 99D | 0.0046 | 1 | 1 |
| Schistosoma mansoni | peptide (allatostatin)-like receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Serotonin receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide f receptor 76f | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptide s receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | serotonin receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | orexin receptor type 2 | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptide Y receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Dopamine receptor protein 2 | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | G-protein coupled receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Serotonin/octopamine receptor family protein 7 | 0.0046 | 1 | 1 |
| Brugia malayi | follicle stimulating hormone receptor | 0.0046 | 1 | 1 |
| Brugia malayi | sulfakinin receptor protein | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | peptide (FMRFamide/neurokinin-3)-like receptor | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide receptor | 0.0046 | 1 | 1 |
| Brugia malayi | G-protein-linked acetylcholine receptor protein 2, putative | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Schistosoma mansoni | biogenic amine (5HT) receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | thyrotropin releasing hormone receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | somatostatin receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | g protein coupled receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | gonadotropin-releasing hormone receptor 2 | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide s receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | peptide (allatostatin:somatostatin) | 0.0046 | 1 | 1 |
| Echinococcus granulosus | tachykinin peptides receptor 99D | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | peptide (FMRFamide/somatostatin)-like receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | neuropeptide F receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Brugia malayi | neuropeptide F receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Serotonin receptor | 0.0046 | 1 | 1 |
| Brugia malayi | G protein-coupled receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine (5HT) receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | alpha 1A adrenergic receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus granulosus | dro:myosuppressin receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | sex peptide receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptides capa receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0572 | 0.0572 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Brugia malayi | Unidentified vitellogenin-linked transcript protein 6, putative | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptide FF receptor 2 | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide Y receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide F-like receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | alpha 1A adrenergic receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Schistosoma mansoni | amine GPCR | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | biogenic amine (5HT) receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | amine GPCR | 0.0046 | 1 | 1 |
| Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | 0.0046 | 1 | 1 |
| Brugia malayi | Tachykinin-like peptides receptor 99D | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus granulosus | neuropeptide receptor A26 | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | g-protein coupled receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | TYRA-2 protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | opsin-like receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus granulosus | g protein coupled receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine (dopamine) receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | fmrfamide receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | growth hormone secretagogue receptor type 1 | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide FF receptor 2 | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | opsin-like receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | biogenic amine 5HT receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | muscarinic acetylcholine (GAR) receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide F-like receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | lamin | 0.0033 | 0.5569 | 0.5569 |
| Brugia malayi | gonadotropin-releasing hormone receptor 2 | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | serotonin receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | biogenic amine (dopamine) receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | dro:myosuppressin receptor | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | g protein coupled receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | pyroglutamylated rfamide peptide receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | histamine h1 receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | G protein coupled receptor 139 | 0.0046 | 1 | 1 |
| Brugia malayi | AKH receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Schistosoma mansoni | myosin xvIII | 0.0046 | 1 | 1 |
| Echinococcus granulosus | 7TM GPCR rhodopsin | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.5372 | 0.5372 |
| Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.5569 | 0.5569 |
| Brugia malayi | putative neuropeptide receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | peptide (FMRFamide/somatostatin)-like receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Brugia malayi | larval opioid receptor | 0.0046 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | g protein linked acetylcholine receptor gar 2a | 0.0046 | 1 | 1 |
| Schistosoma mansoni | neuropeptide receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | tm gpcr rhodopsin | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | tm gpcr rhodopsin | 0.0046 | 1 | 1 |
| Onchocerca volvulus | 0.0046 | 1 | 1 | |
| Echinococcus granulosus | sex peptide receptor | 0.0046 | 1 | 1 |
| Schistosoma mansoni | thyrotropin-releasing hormone receptor | 0.0046 | 1 | 1 |
| Brugia malayi | neuropeptide F receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | neuropeptide receptor A26 | 0.0046 | 1 | 1 |
| Schistosoma mansoni | amine GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | rhodopsin-like orphan GPCR | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.0046 | 1 | 1 |
| Echinococcus granulosus | neuropeptides capa receptor | 0.0046 | 1 | 1 |
| Echinococcus granulosus | fmrfamide receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Echinococcus granulosus | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Echinococcus granulosus | peptide allatostatin:somatostatin | 0.0046 | 1 | 1 |
| Schistosoma mansoni | alpha-1 adrenergic receptor | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | neuropeptide F receptor | 0.0046 | 1 | 1 |
| Echinococcus multilocularis | rhodopsin orphan GPCR | 0.0046 | 1 | 1 |
| Schistosoma mansoni | hypothetical protein | 0.0046 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.5569 | 0.5569 |
| Loa Loa (eye worm) | hypothetical protein | 0.0046 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
| AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
| AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
| AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
| AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
| Activity (binding) | Inhibition of mouse brain MAOB | ChEMBL. | 18834112 | |
| Activity (binding) | Inhibition of mouse brain MAOA | ChEMBL. | 18834112 | |
| Activity (functional) | < 0.1 uM | NO releasing ability of compound measured through formation of nitrite using nNOS (nitric oxide synthases) | ChEMBL. | 11527735 |
| Activity (functional) | < 0.1 uM | NO releasing ability of compound measured through formation of nitrite using iNOS (nitric oxide synthases) | ChEMBL. | 11527735 |
| Activity (functional) | < 0.1 uM | NO releasing ability of compound measured through formation of nitrite using nNOS (nitric oxide synthases) | ChEMBL. | 11527735 |
| Activity (functional) | < 0.1 uM | NO releasing ability of compound measured through formation of nitrite using iNOS (nitric oxide synthases) | ChEMBL. | 11527735 |
| Blood pressure (functional) | = -32 mmHg | Changes in systolic Blood pressure following iv administration at (25 micromol/Kg) anesthetized rats | ChEMBL. | 11520203 |
| Blood pressure (functional) | = -27 mmHg | Tested for the change in systolic blood pressure administered at 25 microg/kg intravenously in anesthetized rats | ChEMBL. | 8411013 |
| Blood pressure (functional) | = -23 mmHg | Changes in diastolic Blood pressure following iv administration at (25 micromol/Kg) anesthetized rats | ChEMBL. | 11520203 |
| Blood pressure (functional) | = -19 mmHg | Tested for the change in diastolic blood pressure administered at 25 microg/kg intravenously in anesthetized rats | ChEMBL. | 8411013 |
| BP (functional) | = -29 mmHg | Change in systolic blood pressure after iv administration of 25 microM/kg in anesthetized rats | ChEMBL. | 10447956 |
| BP (functional) | = -22 mmHg | Change in diastolic blood pressure after iv administration of 25 microM/kg in anesthetized rats | ChEMBL. | 10447956 |
| BP (functional) | = -20 mmHg | Antihypertensive activity of the compound was evaluated in spontaneously hypertensive rat model with base line sytoslic pressure of 174 mmHg by the indirect tail-cuff method at an oral screening dose of 50 mg/Kg | ChEMBL. | 6699886 |
| BP (functional) | = 138 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 4 hours of postdose-2 | ChEMBL. | 7452694 |
| BP (functional) | = 138 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 4 hours of postdose-2 | ChEMBL. | 7452699 |
| BP (functional) | = 146 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 24 hours of postdose-2 | ChEMBL. | 7452694 |
| BP (functional) | = 154 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 4 hours of postdose-1 | ChEMBL. | 7452694 |
| BP (functional) | = 154 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 4 hours of postdose-1 | ChEMBL. | 7452699 |
| BP (functional) | = 163 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 25 mg/kg,po after 4 hours of postdose-1 | ChEMBL. | 7452694 |
| BP (functional) | = 163 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 25 mg/kg,po after 4 hours of postdose-2 | ChEMBL. | 7452694 |
| BP (functional) | = 166 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 24 hours of postdose-1 | ChEMBL. | 7452694 |
| BP (functional) | = 166 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 24 hours of postdose-1 | ChEMBL. | 7452699 |
| BP (functional) | = 181 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 25 mg/kg,po after 24 hours of postdose-1 | ChEMBL. | 7452694 |
| BP (functional) | = 183 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 25 mg/kg,po after 24 hours of postdose-2 | ChEMBL. | 7452694 |
| BP (functional) | = 186 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po after 24 hours of postdose-2 | ChEMBL. | 7452699 |
| BP (functional) | = 187 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po before predose | ChEMBL. | 7452694 |
| BP (functional) | = 187 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 50 mg/kg,po before predose | ChEMBL. | 7452699 |
| BP (functional) | = 194 mmHg | Antihypertensive activity in spontaneously hypertensive rats was measured as average blood pressure at 25 mg/kg,po before predose | ChEMBL. | 7452694 |
| Change (functional) | = -26 % | Percent change in systolic blood pressure (mmHg)in anesthetized rats by i.v. administration | ChEMBL. | 10576697 |
| Change (functional) | = -24 % | Percent change in diastolic blood pressure (mmHg)in anesthetized rats by i.v. administration | ChEMBL. | 10576697 |
| Change (functional) | = -17 % | Maximum rate of rise of the left ventricular isovolumetric pressure in anesthetized rats by i.v. administration | ChEMBL. | 10576697 |
| Change (functional) | = -7 % | Percent change in heart rate expressed in beats / min in anesthetized rats by i.v. administration | ChEMBL. | 10576697 |
| Change in systolic pressure (functional) | = 34 mmHg | Antihypertensive activity was measured for systolic pressure using spontaneous hypertensive rats (SHR) at 10 mg/kg after oral administration | ChEMBL. | 7392034 |
| Concentration (ADMET) | = 2.6 % kg dose g-1 | Distribution of the compound in dog adrenal medulla 30 min after administration. | ChEMBL. | 6694163 |
| Concentration (ADMET) | = 5.1 % kg dose g-1 | Distribution of the compound in dog adrenal medulla 72 hours after administration. | ChEMBL. | 6694163 |
| DA release (functional) | = 2.7 % | The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3) | ChEMBL. | 2374149 |
| DA release (functional) | = 3 % | The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3) | ChEMBL. | 2374149 |
| dP/dt (functional) | = -1090 mmHg s-1 | Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 25 microM/kg in anesthetized rats; ratio given for dP/dt | ChEMBL. | 10447956 |
| dp/dt (functional) | = -863 mmHg s-1 | Maximum rate of rise of the left ventricular isovolumetric pressure administered at 25 microM/kg iv in anesthetized rats | ChEMBL. | 8411013 |
| Heart rate (functional) | = -24 beats min-1 | Change in heart rate after iv administration of 25 microM/kg in anesthetized rats | ChEMBL. | 10447956 |
| Heart rate (functional) | = -18 beats min-1 | Tested for change in heart rate administered at 25 microM/kg iv in anesthetized rats | ChEMBL. | 8411013 |
| IC50 (binding) | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Toxoplasma gondii | ChEMBL. | 20185316 | |
| IC50 (functional) | Antimicrobial activity against Trypanosoma brucei | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Entamoeba histolytica | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Trichomonas vaginalis | ChEMBL. | 20185316 | |
| IC50 (functional) | Antimicrobial activity against Trypanosoma brucei brucei | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Trypanosoma brucei rhodesiense | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CXCR1 (IL-8A) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Leishmania mexicana | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Trypanosoma cruzi | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Leishmania infantum | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Plasmodium falciparum | ChEMBL. | 20185316 | |
| IC50 (functional) | Antimicrobial activity against Cryptosporidium parvum | ChEMBL. | 20185316 | |
| IC50 (functional) | Antimicrobial activity against Leishmania major | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| IC50 (functional) | Antimicrobial activity against Leishmania donovani | ChEMBL. | 20185316 | |
| IC50 (binding) | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| IC50 (binding) | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CXCR1 (IL-8A) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | ChEMBL. | No reference | |
| Ki (binding) | DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) | ChEMBL. | No reference | |
| MABP change (functional) | = -16 mmHg | Blood pressure change in rats after oral administration of 50 mg/kg dose after 4 hours | ChEMBL. | 3735318 |
| MABP change (functional) | = 9 mmHg | Blood pressure change in rats after oral administration of 50 mg/kg dose after 24 hours | ChEMBL. | 3735318 |
| Potency (functional) | = 1.4125 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 5.7255 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
| Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: Inhibitors of USP1/UAF1: Pilot qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504878] | ChEMBL. | No reference |
| Ratio (ADMET) | = 70 | Ratio of the concentration levels determined for the adrenal medulla to the liver after 72 hr; [Adrenal Medulla]/[liver] | ChEMBL. | 6694163 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
Bibliographic References
17 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.